Amino acid
Glutamine
Glutamine's terminal elimination half-life is approximately one hour after an intravenous bolus on the Endari label; the app lists 1 hour.1
Glutamine after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.
Drawn from the half-life in the app's model, ~1 h. The model's figures
- Compound
- Glutamine
- Symbol
- GLN
- Family
- Supplements
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Endari is an L-glutamine oral powder made for Emmaus Medical, and its label describes L-glutamine as an amino acid.1 The label's indication is reducing the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, and it gives 2017 as the initial US approval year.1 The Endari label lists sickle cell disease as its indication, and the trials below in critical illness, burns, glucose handling and exercise were run outside that label.1
The app grades the evidence for glutamine as moderate. The phase 3 sickle cell disease trial was funded by Emmaus Medical, the REDOXS intensive care trial by the Canadian Institutes of Health Research, and the RE-ENERGIZE burns trial by the U.S. Department of Defense and the Canadian Institutes of Health Research.3,4,5
How it works
The Endari label states that "the mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood".1 The label adds that L-glutamine "may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione".1 Sadaf and colleagues write that, because glutamine is one of the precursors of glutathione, "the proposed primary action of l-glutamine in SCD is the mitigation of oxidative damage in erythrocytes by augmenting the intracellular production of glutathione".2
In healthy volunteers, Valencia and colleagues (Oxford Brookes University, Nutrition, 2002) gave oral glutamine at 0.3 g/kg/day for 10 days and measured plasma and whole-blood levels over 24 hours.6 Plasma glutamate rose 116% (P = 0.006) and plasma glutamine 20% (P = 0.046), while whole-blood glutathione was 37% lower (P = 0.00091).6
Greenfield and colleagues (American Journal of Clinical Nutrition, 2009) gave 24 adults a single 30 g oral dose of glutamine, with water and 75 g of glucose on other days, and measured GLP-1, GIP, insulin and glucagon over 120 minutes.7 Circulating GLP-1 increased in all three groups after glutamine, and the authors report that glutamine "stimulated glucagon secretion in all 3 study groups".7
For burns, the RE-ENERGIZE authors state that "glutamine is thought to have beneficial effects on the metabolic and stress response to severe injury".5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1 h
- Bioavailability
- 36%
- Typical dose
- 5–20 g/day
- Route
- Oral
- Time to peak
- ~1.2 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1 h | Terminal elimination half-life approximately one hour after an intravenous bolus on the Endari label; 1.0 ± 0.7 hours after oral doses in a 12-person Emmaus Medical-funded trial; the same trial cites 12 minutes and 67 minutes for two phases after intravenous dosing in an earlier study1,2 |
| Time to peak | ~1.2 h | Mean peak concentration about 30 minutes after a single oral 0.1 g/kg dose, and about one hour after multiple doses, on the label; 1.2 ± 0.9 hours in the Sadaf trial, longer at 0.6 g/kg1,2 |
| Bioavailability | 36% | No absolute oral bioavailability or first-pass extraction percentage is stated in the label or the Sadaf trial; both report that exposure rises less than in proportion to dose1,2 |
| Model | One-compartment | One-compartment model with first-order absorption in the Sadaf population analysis2 |
| Volume of distribution | Not listed | About 750 mL/kg after multiple oral doses on the label; 52.3 L/70 kg in the Sadaf trial1,2 |
The label's time to peak (30 minutes to one hour) is shorter than the app's figure of about 1.2 hours, and the Sadaf mean of 1.2 hours matches it.1,2 The app's notes describe about 64% first-pass extraction and a bioavailability of about 36%; neither the label nor the Sadaf trial reports either number.1,2 After multiple twice-daily oral doses the label reports no accumulation, and no significant change in L-glutamine concentration associated with food.1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Niihara and colleagues, New England Journal of Medicine 20183 | Multicentre, randomised, placebo-controlled, double-blind phase 3 trial, 2:1; funded by Emmaus Medical3 | 230 patients aged 5 to 58 years with sickle cell anemia or sickle β0-thalassemia and a history of two or more pain crises in the previous year3 | L-glutamine 0.3 g/kg per dose twice daily by mouth or placebo; 48 weeks3 | Median pain crises 3.0 with L-glutamine (152 patients) and 4.0 with placebo (78 patients), P=0.005; median hospitalizations 2.0 and 3.0, P=0.005; low-grade nausea, noncardiac chest pain, fatigue and musculoskeletal pain more frequent with L-glutamine3 |
| Sadaf and colleagues, Clinical Pharmacokinetics 20242 | Single-centre, open-label, dose-ascending phase IV pharmacokinetic trial without a placebo group; funded by Emmaus Medical2 | 8 participants with sickle cell disease (children and adults) and 4 adult healthy volunteers2 | 0.1 g/kg twice daily, 0.3 g/kg twice daily and 0.6 g/kg once daily, one level a week for 3 weeks2 | Mean Tmax 1.2 ± 0.9 hours and half-life 1.0 ± 0.7 hours; dose-normalised peak fell as dose rose; five participants reported adverse events, none severe2 |
| Heyland and colleagues, REDOXS, New England Journal of Medicine 20134 | Blinded 2-by-2 factorial randomised trial of glutamine, antioxidants, both or placebo; funded by the Canadian Institutes of Health Research4 | 1223 critically ill adults with multiorgan failure on mechanical ventilation in 40 ICUs in Canada, the United States and Europe4 | Glutamine given intravenously and enterally, started within 24 hours of ICU admission; primary outcome 28-day mortality4 | 28-day mortality 32.4% with glutamine against 27.2% without (adjusted odds ratio 1.28; 95% CI 1.00 to 1.64; P=0.05); in-hospital and 6-month mortality significantly higher with glutamine; no effect on organ failure or infectious complications4 |
| Heyland and colleagues, RE-ENERGIZE, New England Journal of Medicine 20225 | Double-blind, randomised, placebo-controlled trial; funded by the U.S. Department of Defense and the Canadian Institutes of Health Research5 | 1209 randomised and 1200 analysed patients with deep second- or third-degree burns (mean burn size 33% of body-surface area)5 | Enteral glutamine 0.5 g/kg/day or placebo, until 7 days after the last skin graft, discharge from the acute care unit, or 3 months, whichever came first5 | Median time to discharge alive 40 days (glutamine, 596 patients) and 38 days (placebo, 604); subdistribution hazard ratio 0.91 (95% CI 0.80 to 1.04; P = 0.17); 6-month mortality 17.2% against 16.2%5 |
| Valencia and colleagues, Nutrition 20026 | Before-and-after measurement in volunteers; funder not stated in the summary read6 | Healthy volunteers; number not stated in the summary read6 | Oral glutamine 0.3 g/kg/day for 10 days6 | Plasma glutamate +116% (P = 0.006) and glutamine +20% (P = 0.046); whole-blood glutathione 37% lower (P = 0.00091)6 |
| Greenfield and colleagues, American Journal of Clinical Nutrition 20097 | Randomised crossover of glucose, glutamine and water on three days; no placebo capsule, water as the comparator; no conflict of interest reported7 | 24 adults: 8 lean, 8 obese with type 2 diabetes or impaired glucose tolerance, 8 obese controls7 | Single oral glutamine dose of 30 g; plasma measured for 120 minutes7 | GLP-1 peaked at 30 minutes at 22.5 ± 3.4 pmol/L in the lean group, 17.9 ± 1.1 in obese controls and 17.3 ± 3.4 in obese participants with type 2 diabetes or impaired glucose tolerance; GIP, insulin and glucagon also rose7 |
| Legault and colleagues, International Journal of Sport Nutrition and Exercise Metabolism 20158 | Double-blind, randomised, placebo-controlled crossover trial with maltodextrin placebo8 | 16 healthy participants (8 women, 8 men), age 22 ± 4 years8 | L-glutamine 0.3 g/kg/day plus 0.3 g/kg/day maltodextrin, once daily for 72 hours8 | Relative peak torque at 180°/sec 71 ± 8% against 66 ± 9% immediately after eccentric exercise and 91 ± 8% against 86 ± 7% at 72 hours; lower soreness ratings at 24, 48 and 72 hours8 |
Deeper analysis: the phase 3 trial in sickle cell disease
Niihara and colleagues reported the trial in the New England Journal of Medicine in 2018 as a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of pharmaceutical-grade L-glutamine in patients with sickle cell anemia or sickle β0-thalassemia.3 The report states that "two thirds of the patients in both trial groups received concomitant hydroxyurea", and the label lists exclusions including blood products within 3 weeks, renal insufficiency, uncontrolled liver disease, pregnancy and lactation.3,1 The primary result was a median of 3.0 pain crises on L-glutamine against 4.0 on placebo (P=0.005), with a median of 2.0 against 3.0 hospitalizations (P=0.005).3 The registry entry gives the primary analysis as a Cochran-Mantel-Haenszel test with P = 0.0052, and states that the final analysis was performed at the 0.045 significance level.9 The registry also lists emergency room or medical facility visits for sickle cell pain as a secondary outcome, with a median of 1 in both groups and a P value of 0.0888.9 The label reports a hazard ratio for time to first crisis of 0.69 (95% CI 0.52, 0.93).1 The label also reports a recurrent-event intensity rate ratio of 0.75, with 95% confidence intervals of (0.62, 0.90) by one method and (0.55, 1.01) by another, so the second interval includes 1.1 The label states that the clinical benefit "was observed irrespective of hydroxyurea use".1 The registry lists 97 of 152 participants on L-glutamine and 59 of 78 on placebo as completing the study, so 55 and 19 did not complete.9 Adverse events in the registry's safety population include serious events in 118 of 151 participants on L-glutamine and 68 of 78 on placebo.9 The label states that serious adverse reactions "were reported in both treatment groups, more frequently in the placebo group", that 5 patients (2.7%) discontinued because of adverse reactions, and that three deaths (3 of 187, 1.6%) occurred in the Endari group and none in the placebo group, none considered related to Endari.1 The registry names Emmaus Medical, Inc. as lead sponsor, and the journal affiliations place four authors (Y.N., L.T.T., R.L.R. and C.W.S.) at Emmaus Medical, Torrance.9,3 The report's summary does not reproduce the authors' own statement of limitations, so none is quoted here.3
Deeper analysis: REDOXS in critically ill adults
Heyland and colleagues, for the Canadian Critical Care Trials Group, reported REDOXS in the New England Journal of Medicine in 2013: 1223 critically ill adults with multiorgan failure on mechanical ventilation in 40 ICUs were randomised to glutamine, antioxidants, both or placebo.4 The registry gives the glutamine arms as 0.35 g/kg/day parenterally and 30 g/day enterally.10 The primary outcome was 28-day mortality, and the authors set "a P value of less than 0.044 at the final analysis" as the threshold for significance because of the interim-analysis plan.4 The 28-day result (32.4% against 27.2%, adjusted odds ratio 1.28, 95% CI 1.00 to 1.64, P=0.05) is described by the authors as "a trend toward increased mortality".4 In-hospital and 6-month mortality were "significantly higher" among those who received glutamine, and glutamine "had no effect on rates of organ failure or infectious complications".4 The authors report "no differences among the groups with respect to serious adverse events (P=0.83)".4 The authors conclude that "glutamine was associated with an increase in mortality among critically ill patients with multiorgan failure".4 The trial was funded by the Canadian Institutes of Health Research; the registry lists Daren K. Heyland, the first author, as lead sponsor and Fresenius Kabi (class INDUSTRY) as a collaborator.4,10 The registry lists the enteral REDOX formula and the enteral placebo formula as from Fresenius Kabi, Germany.10 The summary read does not reproduce the authors' statement of limitations or disclosures, so none is quoted here.4
Deeper analysis: RE-ENERGIZE in burn injury
Heyland and colleagues reported RE-ENERGIZE in the New England Journal of Medicine in 2022 as a double-blind, randomised, placebo-controlled trial of enteral glutamine 0.5 g/kg/day in patients with deep second- or third-degree burns.5 The primary outcome was time to discharge alive from the hospital, censored at 90 days, analysed with subdistribution hazard ratios that treated death as a competing risk.5 Median time to discharge alive was 40 days (interquartile range 24 to 87) with glutamine and 38 days (22 to 75) with placebo, a subdistribution hazard ratio of 0.91 (95% CI 0.80 to 1.04; P = 0.17).5 Mortality at 6 months was 17.2% with glutamine and 16.2% with placebo (hazard ratio for death 1.06; 95% CI 0.80 to 1.41), and "no substantial between-group differences in serious adverse events were observed".5 The authors conclude that "supplemental glutamine did not reduce the time to discharge alive from the hospital".5 The registry lists the trial's overall status as UNKNOWN, Daren K. Heyland as lead sponsor and the Canadian Institutes of Health Research as a collaborator.11 The summary read does not reproduce the authors' statement of limitations or disclosures, so none is quoted here.5
Deeper analysis: the Sadaf pharmacokinetic trial
Sadaf and colleagues (Cincinnati Children's Hospital Medical Center) ran a single-centre, open-label, phase IV trial from January to June 2021 in 8 people with sickle cell disease and 4 adult healthy volunteers, each given three ascending oral doses of Endari powder over 3 weeks.2 The authors report in their key points that "doses higher than 0.3 g/kg do not yield substantially higher blood concentrations".2 Five participants reported adverse events, "none was severe"; gastrointestinal complaints (dyspepsia, nausea, vomiting and diarrhea) were most common, occurred mostly at 0.6 g/kg, and led to early discontinuation in one participant.2 Blood urea nitrogen rose from 8.8 to 12.5 mg/dL (p = 0.004) while creatinine stayed at 0.63 mg/dL (p = 0.887).2 The authors name the sparse sampling scheme in some patients as a limitation, "causing difficulties in conducting a robust NCA in all patients", and add that "we also studied a small number of participants, which may have limited our ability to detect some inter-individual differences".2 The study was funded by Emmaus Medical, "the manufacturer of Endari", and the authors declare no conflicts of interest directly relevant to the content of the article.2
Doses reported in studies and on labels
The app lists a typical range of 5 to 20 g/day; the label dose depends on body weight and is given twice daily.
| Source | Who and route | Dose | Length and comparator |
|---|---|---|---|
| Endari label (US)1 | Adults and children 5 years and older with sickle cell disease; oral | 5 grams to 15 grams twice daily based on body weight, which is 10 to 30 g per day; packets contain 5 g and the carton states no more than 6 packets per day1 | Label dosing; the label's efficacy trial used placebo for 48 weeks1 |
| Niihara 2018 and registry3,9 | 230 patients aged 5 to 58 years with sickle cell disease; oral | 0.3 g/kg per dose twice daily, with a registry upper limit of 30 g per day3,9 | 48 weeks; placebo (100% maltodextrin) comparator; 152 against 78 patients3,9 |
| Sadaf 20242 | 8 people with sickle cell disease and 4 healthy adults; oral | 0.1 g/kg twice daily, 0.3 g/kg twice daily, 0.6 g/kg once daily2 | One level per week for 3 weeks; no placebo group2 |
| REDOXS 2013 and registry4,10 | 1223 critically ill adults; intravenous and enteral | 0.35 g/kg/day intravenously and 30 g/day enterally in the glutamine arms10 | Started within 24 hours of ICU admission; placebo comparator; 2-by-2 factorial with antioxidants4 |
| RE-ENERGIZE 2022 and registry5,11 | 1200 analysed patients with severe burns; enteral by feeding tube or by mouth | 0.5 g/kg/day, given every 4 hours by tube or three or four times a day by mouth5,11 | Up to 3 months or until 7 days after the last graft or discharge from the acute care unit; placebo comparator5 |
| Valencia 2002; Greenfield 2009; Legault 20156,7,8 | Healthy volunteers, 24 adults including people with diabetes, and 16 healthy adults; oral | 0.3 g/kg/day; a single 30 g dose; 0.3 g/kg/day6,7,8 | 10 days; one day against water and glucose; 72 hours against maltodextrin6,7,8 |
Side effects reported
The label lists as most common adverse reactions "constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain", with an incidence above 10% in Endari-treated patients.1 These come from 187 Endari-treated patients and 111 placebo patients in two placebo-controlled trials (a phase 3 study, n=230, and a phase 2 study, n=70) in sickle cell anemia or sickle β0-thalassemia.1 In the phase 3 trial report, "low-grade nausea, noncardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently" with L-glutamine than with placebo.3 The label reports discontinuation for adverse reactions in 2.7% (n=5) of Endari patients, and three deaths in the Endari group against none on placebo, none considered related to Endari.1 In the REDOXS trial in critically ill adults, 28-day mortality was 32.4% with glutamine against 27.2% without (P=0.05), which the authors describe as a trend toward increased mortality; in-hospital and 6-month mortality were significantly higher with glutamine, and there was no group difference in serious adverse events (P=0.83).4 In RE-ENERGIZE, "no substantial between-group differences in serious adverse events were observed" and 6-month mortality was 17.2% against 16.2%.5 The label's overdosage section reports that single oral doses of about 20 to 22 g/kg in mice, 8 to 11 g/kg in rats and 19 g/kg in rabbits were lethal; these are animal results.1 The label states that there are no available data on Endari use in pregnant women, and no data on its presence in human milk.1 The label states that safety and effectiveness in children with sickle cell disease younger than 5 years have not been established.1
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor for glutamine. Sadaf and colleagues reported blood urea nitrogen, creatinine and ammonia results, and state that there were "no changes in electrolytes, hepatic enzymes, and coagulation testing (data not shown)".2
Regulatory and anti-doping status
Sources in this part
The Endari label gives 2017 as the initial US approval year and an indication for reducing the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.1 A text search of the World Anti-Doping Agency Prohibited List 2026 document for "glutamine" returned no match; the search covered that one document.12
Storage and handling
Sources in this part
What is not known
The sources read do not give an absolute oral bioavailability for glutamine or the share extracted on first pass, so the app's 36% stands without a reported figure beside it.1,2 The label states that the pharmacokinetics of Endari has not been studied in people with renal or hepatic impairment, and that no drug interaction studies have been conducted.1 The two intensive care trials used different routes and amounts (intravenous plus enteral in REDOXS, enteral in RE-ENERGIZE) in different populations (multiorgan failure on mechanical ventilation in REDOXS, deep second- or third-degree burns in RE-ENERGIZE).4,5 The authors' own statements of limitations are not quoted for the phase 3 trial, REDOXS or RE-ENERGIZE, because only the journal summaries of those reports were read.3,4,5
Frequently asked questions
Is glutamine approved by the FDA?
The FDA-approved Endari label lists L-glutamine oral powder with an initial US approval year of 2017 for reducing the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.1
What did the phase 3 trial of glutamine in sickle cell disease find?
Niihara and colleagues reported a median of 3.0 pain crises with L-glutamine against 4.0 with placebo over 48 weeks (P=0.005) in 230 patients, and a median of 2.0 against 3.0 hospitalizations (P=0.005).3 The trial was funded by Emmaus Medical, and the registry lists 55 of 152 participants on L-glutamine and 19 of 78 on placebo as not completing it.3,9
Did glutamine change mortality in critically ill patients?
In REDOXS, 28-day mortality was 32.4% with glutamine and 27.2% without (adjusted odds ratio 1.28; 95% CI 1.00 to 1.64; P=0.05) in 1223 adults with multiorgan failure.4 In RE-ENERGIZE, 6-month mortality in burn patients was 17.2% with glutamine and 16.2% with placebo (hazard ratio 1.06; 95% CI 0.80 to 1.41).5
What side effects were reported with glutamine in trials?
The label lists constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain and chest pain as the most common adverse reactions in sickle cell disease trials.1 The label also reports discontinuation because of adverse reactions in 2.7% (n=5) of Endari patients and three deaths in the Endari group against none on placebo, none considered related to Endari, and the REDOXS trial in critically ill adults reported significantly higher in-hospital and 6-month mortality with glutamine.1,4
Guides, tools and comparisons
References
- Emmaus Medical. Endari (L-glutamine oral powder). US prescribing information, DailyMed record version 10, 2025. DailyMed label
- Sadaf A, et al. A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clin Pharmacokinet 2024. PMID 38401036
- Niihara Y, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 2018. PMID 30021096
- Heyland D, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013. PMID 23594003
- Heyland DK, et al. A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries. N Engl J Med 2022. PMID 36082909
- Valencia E, et al. Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. Nutrition 2002. PMID 11985937
- Greenfield JR, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009. PMID 19056578
- Legault Z, et al. The Influence of Oral L-Glutamine Supplementation on Muscle Strength Recovery and Soreness Following Unilateral Knee Extension Eccentric Exercise. Int J Sport Nutr Exerc Metab 2015. PMID 25811544
- ClinicalTrials.gov. NCT01179217. A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia. Emmaus Medical, Inc. NCT01179217
- ClinicalTrials.gov. NCT00133978. Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients. Heyland DK. NCT00133978
- ClinicalTrials.gov. NCT00985205. The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury. Heyland DK. NCT00985205
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list